NCT03580668View on ClinicalTrials.gov

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide

CompletedOBSERVATIONAL
Enrollment

201

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions
HIV-1-infection
Interventions
DRUG

B/F/TAF

B/F/TAF administered in accordance with the approved product monograph

Trial Locations (6)

H2L 4E9

Clinique Medicale du Quartier Latin, Montreal

K1N 6N5

University of Ottawa, Ottawa

S4P 0W5

Regina General Hospital, Regina

M4T3A7

St. Clair Medical Association/Balmoral Clinic, Toronto

M5G 1K2

Maple Leaf Research, Toronto

V6Z 2T1

Spectrum Health, Vancouver

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT03580668 - Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide | Biotech Hunter | Biotech Hunter